Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DV2CR7
|
|||
| Drug Name |
AMG 570
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Systemic lupus erythematosus [ICD-11: 4A40.0; ICD-9: 710] | Phase 2 | [1] | |
| Company |
Amgen
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | B-cell-activating factor (TNFSF13B) | Target Info | Inhibitor | [2] |
| B7-related protein 1 (B7RP1) | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| NF-kappa B signaling pathway | ||||
| Intestinal immune network for IgA production | ||||
| Rheumatoid arthritis | ||||
| Cell adhesion molecules (CAMs) | ||||
| Reactome | TNFR2 non-canonical NF-kB pathway | |||
| TNFs bind their physiological receptors | ||||
| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | ||||
| Costimulation by the CD28 family | ||||
| WikiPathways | Spinal Cord Injury | |||
| Costimulation by the CD28 family | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04058028) Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE). U.S. National Institutes of Health. | |||
| REF 2 | Development of an ICOSL and BAFF bispecific inhibitor AMG 570 for systemic lupus erythematosus treatment. Clin Exp Rheumatol. Nov-Dec 2019;37(6):906-914. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.